

Q. - 1 8/7/02 1653-PATENT

Attorney Docket No. 213373

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Marcu et al.

Application No. 09/936,449

Filed: September 12, 2001

For:

METHOD OF INHIBITING A CHAPERONE PROTEIN

Group Art Unit: Unassigned

Examiner: Unassigned

CH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

COPY OF PAPERS ORIGINALLY FILED

Commissioner for Patents Washington, D.C. 20231

Pursuant to 37 CFR 1.97 and 1.98, the references listed on the enclosed Form PTO-1449 and/or Substitute Form PTO-1449 ("Form 1449") are submitted for consideration by the Examiner in the examination of the above-identified patent application.

The full consideration of the references in their entirety by the Examiner is respectfully requested and encouraged. Also, it is respectfully requested that the references be entered into the record of the present application and that the Examiner place his or her initials in the appropriate area on the enclosed Form 1449, thereby indicating the Examiner's consideration of each of the references.

The submission of the references listed on the Form 1449 is for the purpose of providing a complete record and is not a concession that the references listed thereon are prior art to the invention claimed in the patent application. The right is expressly reserved to establish an invention date earlier than the above-identified filing date in order to remove any reference submitted herewith as prior art should it be deemed appropriate to do so.

Further, the submission of the references is not to be taken as a concession that any reference represents art that is relevant or analogous to the claimed invention. Accordingly, the right to argue that any reference is not properly within the scope of prior art relevant to an examination of the claims in the above-identified application is also expressly reserved.

The Information Disclosure Statement is being filed:

within any one of the following time periods: (a) within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d); (b) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 of an international application; (c) before the mailing date of a first Office Action on the merits; or (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

In re Appln. of Marcu et al. Application No. 09/936,449

	after (a), (b), (c) or (d) above, but before the mailing date of a final action under					
		37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and includes <i>one</i> of:				
		the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below).				
	\Box	the fee of \$180 set forth in 37 CFR 1.17(p) (see "Fees" below).				
	under and or 37 CFI	the mailing date of a final action under 37 CFR 1.113 or a Notice of Allowance 37 CFR 1.311, or an action that otherwise closes prosecution in the application, nor before payment of the issue fee, and includes the Statement under R 1.97(e) (see "Statement under 37 CFR 1.97(e)" below), and the fee of \$180 as the in 37 CFR 1.17(p) (see "Fees" below).				
	after the mailing date of a Notice of Allowance under 37 CFR 1.311, and on or before payment of the issue fee, and within thirty days of receiving each item of information contained in the Information Disclosure Statement, and includes the Statement under 37 CFR 1.704(d) (see "Statement under 37 CFR 1.704(d)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below). NOTE: This is for original applications except applications for a design patent, filed on or after May 29, 2000, wherein a paper containing only an Information Disclosure Statement in compliance with 37 CFR 1.97 and 1.98 is being filed.					
Copie	s of the	References				
\boxtimes	Attach	s of the references listed on the enclosed Form 1449 are enclosed herewith. ed to each reference not in the English language is a concise explanation of the nce pursuant to 37 CFR 1.98(a)(3).				
	A copy	y of the foreign search report is enclosed herewith.				
	parent furnish submir The H accord Proced relied	eferences listed on the enclosed Form 1449 were previously identified in the application(s) of the present application, and copies of the references were need at that time. Accordingly, additional copies of the references are not ted herewith, so as not to burden the file with duplicate copies of references. Examiner is respectfully requested to carefully review the references in lance with the requirements set out in the Manual of Patent Examining dure. In accordance with 37 CFR 1.98(d), the details of the parent application(s) upon for an earlier filing date under 35 USC 120 in which copies of the pages were previously furnished are set out below:				

In re Appln. of Marcu et al. Application No. 09/936,449

U.S. APPLICATIONS			Status (check one)					
U.	S. APPLICATIONS	U.S. FILING DATE	PATENTED	PENDING	ABANDONED			
1.								
2.								
3.			<u> </u>	_				
Stater	Statement under 37 CFR 1.97(e)							
	The undersigned hereby states that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.							
	The undersigned hereby states that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.							
Stater	nent under 37 CFR	1.704(d)						
	The undersigned hereby states that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 CFR 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.							
Fees		•						
	No fee is owed by the IDS Fee of \$15	the applicant(s). 80 under 37 CFR 1.17(p) is enclosed h	erewith.				
Method of Payment of Fees								
	Charge Deposit Ac	in the amount of \$ count No. 12-1216 in the is enclosed for that pur		. (A d	luplicate copy of			
Authorization to Charge Additional Fees								
\boxtimes	If any additional for that purpose.)	ees are owed in connecti No. 12-1216. (A duplica	ion with this coate copy of thi	ommunications communica	on, please charge ation is enclosed			

In re Appln. of Marcu et al. Application No. 09/936,449

Instructions as to Overpayment

 \bowtie

Credit Account No. 12-1216. Refund

Carol Larcher, Reg. No. 35,243 LEVDIG, WOIT & MAYER, LTD. Two Prudential Plaza, Suite 4900

180 North Stetson

Chicago, Illinois 60601-6780 (312) 616-5600 (telephone) (312) 616-5700 (facsimile)

Date: December 11, 2001

CERTIFICATE OF MAILING

I hereby certify that this INFORMATION DISCLOSURE STATEMENT (along with any documents referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231.

Date: December 11, 201

IDS (Rev. 2/1/2001)

	•
Please type a plus sign (+) inside this box ->	+

				Complete if Known			
Substitute for fo	rm 1449A/B/PTO			Application Number	09/936,449	O.E	
INEC	I IAOIT A BAGI)IC	CLOCUDE	Filing Date	September 12, 2	200	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				First Named Inventor	Marcu et al.	70 5	
				Group Art Unit	Unassigned	JAN 1 7 2002 🔄	
	(Use as many sheets	s as ne	cessary)	Examiner Name	Unassigned	3	
Sheet	1	of	1	Attorney Docket Number	213373	TENO TO DEMAN	

		OTHER - NON PATENT LITERATURE DOCUMENTS		slation		
Examiner	Doc.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book,				
Initials	No.	magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.				
	AA	JOHNSON et al., Mol. Endocrinol., 9(6):670-678 (1995)		<u> </u>		
	ΑB	SCHULTE et al., Cell Stress & Chaperones, 3(2):100-108 (1998)				
	AC	SULLIVAN et al., J. Biol. Chem., 272(12):8007-8012 (March 1997)				
	ΑD	WHITESELL et al., Proc. Natl. Acad. Sci. USA, 91:8324-8328 (August 1994)		<u> </u>		
				-		
			 			
			<u> </u>			
			-			
				 		
				 		
			 			
			 			
-						
			ļ	ļ		
	_					
			\vdash	<u> </u>		
			ļ	 		
			-			
			<u> </u>	<u> </u>		

Examiner Signature	Date Considered		

^{*} A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

⁺ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).